N-((3-Fluoro-4-((2-(1-Methyl-1H-Imidazol-4-Yl)Thieno[3,2-B]Pyridin-7-Yl)Oxy)Phenyl)Carbamothioyl)-2-Phenylacetamide N-((3-氟-4-((2-(1-甲基-1H-咪唑-4-基)噻吩并[3,2-b]吡啶-7-基)氧基)苯基)硫代氨基甲酰基)-2-苯乙酰胺
CAS 875337-44-3 MFCD N/A
化学结构图
SMILES: Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1
化学属性
| Mol. Weight | 517.6 |
|---|---|
| Appearance | Solid powder |
| Solubility | Soluble in DMSO, not in water |
别名和识别编码
| Chemical Name | N-((3-Fluoro-4-((2-(1-Methyl-1H-Imidazol-4-Yl)Thieno[3,2-B]Pyridin-7-Yl)Oxy)Phenyl)Carbamothioyl)-2-Phenylacetamide |
|---|---|
| Chemical Name Translation | N-((3-氟-4-((2-(1-甲基-1H-咪唑-4-基)噻吩并[3,2-b]吡啶-7-基)氧基)苯基)硫代氨基甲酰基)-2-苯乙酰胺 |
| Formula | C26H20FN5O2S2 |
| Synonym | MGCD-265-analog; MGCD 265-analog; MGCD265-analog. Glesatinib-analog. |
| IUPAC Name | N-((3-fluoro-4-((2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)carbamothioyl)-2-phenylacetamide |
| InChIKey | UFICVEHDQUKCEA-UHFFFAOYSA-N |
| InChI | InChI=1S/C26H20FN5O2S2/c1-32-14-20(29-15-32)23-13-19-25(36-23)22(9-10-28-19)34-21-8-7-17(12-18(21)27)30-26(35)31-24(33)11-16-5-3-2-4-6-16/h2-10,12-15H,11H2,1H3,(H2,30,31,33,35) |
| Canonical SMILES | O=C(NC(NC1=CC=C(OC2=C3C(C=C(C4=CN(C)C=N4)S3)=NC=C2)C(F)=C1)=S)CC5=CC=CC=C5 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
产品应用
- MGCD265-analog, CAS#875337-44-3, is structurally related to MGCD-265 (Glesatinib). MGCD-265-analog is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity. MGCD-265-analog was introduced to the research community due to the wrong structure published in some database and publications. MGCD-265-analog has been sold as MGCD-265 by many reagent vendors since 2012. As of 4/28/2016, many drug-related database and suppliers still listed a wrong structure for MGCD-265. MGCD-265 (Glesatinib) has CAS#936694-12-1.
